Back to search
Hepatecellular Carcinoma
Clinical trial pipeline · Data from ClinicalTrials.gov
See which Hepatecellular Carcinoma trials you may qualify forClinical trial pipeline · Data from ClinicalTrials.gov
See which Hepatecellular Carcinoma trials you may qualify forThe goal of this prospective, single-arm, multi-center Phase II clinical trial is to evaluate the clinical efficacy and safety of QL1706 combined with bevacizum…
This observational study aims to validate a deep learning model for predicting aggressive recurrence patterns in patients with early-stage liver cancer (HCC) af…
1.1. Main Objectives The objective response rate (ORR) determined by the researchers based on RECIST v1.1 was used to evaluate the efficacy of systemic therapy…
Primary liver tumors, with hepatocellular carcinoma (HCC) accounting for 80%, represent 6% of global cancer incidence and 9% of global cancer-associated mortali…
Hepatocellular carcinoma (HCC) surveillance is frequently underutilized, and currently available biomarkers, such as alpha-fetoprotein (AFP), demonstrate subopt…